Original Research
Published on 06 Nov 2025
Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a real-world retrospective study
in Head and Neck Cancer
- 514 views